APCCC 2024: How Do Non-DDR Genomic Alterations Influence Management of Patients with Advanced Prostate Cancer?
APCCC 2024, prostate cancer, metastatic castrate-sensitive prostate cancer (mCSPC), non-DNA Damage Response (DDR) genomic alteration, Non-DDR Genomic Alterations, Advanced Prostate Cancer, SWOG2312 trial, RET fusions, selpercatinib, larotrectinib, entrectinib, BRAFV600E, dabrafenib, trametinib, HER2 overexpression, fam-trastuzumab deruxtecan, Microsatellite instability-high (MSI-H), tumor mutational burden high (TMB-H), DNA mismatch repair deficiency (dMMR), pembrolizumab, dostarlimab, positive AR-V7 splice variants, SWOG2312 trial, cabazitaxel, enzalutamide.